Treatment with Nonmitogenic Anti-CD3 Monoclonal Antibody Induces CD4+ T Cell Unresponsiveness and Functional Reversal of Established Experimental Autoimmune Encephalomyelitis1

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Immunology

• Publication date

  2005-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.174.8.4525PMID 15814673
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

  2003cited by this paper
• CD3-specific antibody-induced active tolerance: from bench to bedside

  2003cited by this paper
• TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

  2003influential reference
• Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis

  2003cited by this paper
• Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala)

  2003cited by this paper
• CD28/B7 Regulation of Anti-CD3-Mediated Immunosuppression In Vivo1

  2003cited by this paper
• Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.

  2002cited by this paper
• CD4+CD25+ suppressor T cells: more questions than answers

  2002influential reference
• Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

  2002cited by this paper
• EncephalomyelitisExperimental Autoimmune System Inflammation During Active Immune Responses and Central Nervous Cells Suppress Antigen-Specific Autoreactive Regulatory T + CD25+ Cutting Edge: CD4

  2002cited by this paper
• Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

  2002cited by this paper
• Nonmitogenic CD3 Antibody Reverses Virally Induced (Rat Insulin Promoter-Lymphocytic Choriomeningitis Virus) Autoimmune Diabetes Without Impeding Viral Clearance1

  2002cited by this paper
• Immunotherapy of insulin-dependent diabetes mellitus.

  2002cited by this paper
• Specificity requirements for selection and effector functions of CD25+4+ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice

  2002cited by this paper
• De Novo Central Nervous System Processing of Myelin Antigen Is Required for the Initiation of Experimental Autoimmune Encephalomyelitis1

  2002cited by this paper
• Regulatory T cells in spontaneous autoimmune encephalomyelitis

  2001cited by this paper
• Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4.

  2001cited by this paper
• Immunotherapy of insulin-dependent diabetes mellitus.

  2001cited by this paper
• The T-cell repertoire available for recognition of self-antigens.

  2001cited by this paper
• Suppressor T cells – they’re back and critical for regulation of autoimmunity!

  2001cited by this paper
• B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

  2000cited by this paper
• Pathologic Role and Temporal Appearance of Newly Emerging Autoepitopes in Relapsing Experimental Autoimmune Encephalomyelitis1

  2000cited by this paper
• Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis.

  1998influential reference
• Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets.

  1998cited by this paper
• CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells.

  1998cited by this paper
• Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease

  1998cited by this paper
• Nonmitogenic Anti-CD3 Monoclonal Antibodies Deliver a Partial T Cell Receptor Signal and Induce Clonal Anergy

  1997cited by this paper
• CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice.

  1997cited by this paper
• An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.

  1995cited by this paper
• Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

  1995cited by this paper
• B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy.

  1995cited by this paper
• Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis

  1995cited by this paper
• Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.

  1994cited by this paper
• Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease

  1994cited by this paper
• Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma

  1993cited by this paper
• Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis.

  1993cited by this paper
• Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice.

  1992cited by this paper
• Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain

  1992cited by this paper
• Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial.

  1991cited by this paper
• OKT3E, AN ANTI‐CD3 ANTIBODY THAT DOES NOT ELICIT SIDE EFFECTS OR ANTIIDIOTYPE RESPONSES IN CHIMPANZEES

  1991cited by this paper
• EVIDENCE THAT PENTOXIFYLLINE REDUCES ANTI‐CD3 MONOCLONAL ANTIBODY‐INDUCED CYTOKINE RELEASE SYNDROME

  1991cited by this paper
• Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice.

  1991cited by this paper
• Hypothermia and hypoglycemia induced by anti‐CD3 monoclonal antibody in mice: Role of tumor necrosis factor

  1990cited by this paper
• Cytokine‐related syndrome following injection of anti‐CD3 monoclonal antibody: Further evidence for transient in vivo T cell activation

  1990cited by this paper
• Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb.

  1990cited by this paper
• Treatment of acute cellular kidney allograft rejection with T10B9.1A-31A anti T-cell monoclonal antibody.

  1989cited by this paper
• Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes.

  1989cited by this paper
• Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes

  1989cited by this paper
• Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells.

  1989cited by this paper
• Suppression of the humoral response to anti-CD3 monoclonal antibody.

  1989cited by this paper
• Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses.

  1988cited by this paper
• Identification of a monoclonal antibody specific for a murine T3 polypeptide.

  1987cited by this paper
• Monoclonal antibody-induced inhibition of relapsing EAE in SJL/J mice correlates with inhibition of neuroantigen-specific cell-mediated immune responses.

  1987cited by this paper
• Chronologic neuropathology of relapsing experimental allergic encephalomyelitis in the mouse.

  1982cited by this paper
• CH3 domain of IgG as binding site to Fc receptor on mouse lymphocytes

  1975influential reference

• TCF1highPD-1+Ly108+CD8+ T Cells Are Associated with Graft Preservation in Sensitized Mice Treated with Non–Fc Receptor–Binding CD3 Antibodies

  2024cites this paper
• Anti‐CD3 inhibits circulatory and tissue‐resident memory CD4 T cells that drive asthma exacerbations in mice

  2023cites this paper
• Induction of long-term tolerance to a specific antigen using anti-CD3 lipid nanoparticles following gene therapy

  2023cites this paper
• Modulating T Cell Responses by Targeting CD3

  2023cites this paper
• CD3e-immunotoxin spares CD62Llo Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3ehi T cells

  2022cites this paper
• Reduction of Cell Surface T-Cell Receptor by Non-Mitogenic CD3 Antibody to Mitigate Murine Lupus

  2022influential citation
• Regulatory T cell therapy: Current and future design perspectives.

  2020cites this paper
• Intestinal Delivery of Proinsulin and IL-10 via Lactococcus lactis Combined With Low-Dose Anti-CD3 Restores Tolerance Outside the Window of Acute Type 1 Diabetes Diagnosis

  2020cites this paper
• Pathogenesis and Medical Management of Thyroid Eye Disease

  2020cites this paper
• Effect of partial depletion of CD25+ T cells on neurological deficit and tissue damage in acute cerebral ischemia rat models

  2018cites this paper
• Molecular Mechanisms of T Cells Activation by Dendritic Cells in Autoimmune Diseases

  2018cites this paper
• T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target

  2018cites this paper
• Route of Antigen Presentation Can Determine the Selection of Foxp3-Dependent or Foxp3-Independent Dominant Immune Tolerance

  2018cites this paper
• Potential targeting of B7‐H4 for the treatment of cancer

  2017cites this paper
• Anemoside A3 ameliorates experimental autoimmune encephalomyelitis by modulating T helper 17 cell response

  2017cites this paper
• Revisiting the phenotypic and genetic profiling of anergic T cells mediating long-term transplant tolerance

  2017cites this paper
• Anti‐CD3 antibody therapy attenuates the progression of hypertension in female mice with systemic lupus erythematosus

  2017cites this paper
• Regulatory mechanisms of immune tolerance in type 1 diabetes and their failures.

  2016cites this paper
• Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside.

  2016cites this paper
• Tissue Non-specific Alkaline Phosphatase Expression is Needed for the Full Stimulation of T Cells and T Cell-Dependent Colitis

  2016cites this paper
• Control of Immune Response to Allogeneic Embryonic Stem Cells by CD3 Antibody–Mediated Operational Tolerance Induction

  2016cites this paper
• Estudo da interação com o antígeno de um anticorpo Anti-CD3 humano

  2016cites this paper
• Differential Sensitivity of Regulatory and Effector T Cells to Cell Death: A Prerequisite for Transplant Tolerance

  2015cites this paper
• Preserving Regulatory T Cells Selectively Depleting Pathogenic Cells while Anti-CD3 Therapy Promotes Tolerance by

  2015cites this paper
• Correction: Determining Disease Intervention Strategies Using Spatially Resolved Simulations

  2015cites this paper
• Biotherapies targeting T and B cells: from immune suppression to immune tolerance.

  2015cites this paper
• The Need for Immune Modulation Despite Regenerative Medicine

  2014cites this paper
• Novel CD3‐specific antibody induces immunosuppression via impaired phosphorylation of LAT and PLCγ1 following T‐cell stimulation

  2014cites this paper
• A Biodegradable Nanoparticle Platform for the Induction of Antigen-Specific Immune Tolerance for Treatment of Autoimmune Disease

  2014cites this paper
• cytokine production to favor a Th1 response by a regulatory CD4+CD25+-dependent mechanism and by shifting Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice

  2013cites this paper
• Gut immune system and oral tolerance

  2013cites this paper
• Differential Response of Regulatory and Conventional CD4+ Lymphocytes to CD3 Engagement: Clues to a Possible Mechanism of Anti-CD3 Action?

  2013cites this paper
• Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

  2013cites this paper
• Engagement: Clues to a Possible Mechanism Lymphocytes to CD3 + Conventional CD4 Differential Response of Regulatory and

  2013cites this paper
• Delayed Anti-CD3 Therapy Results in Depletion of Alloreactive T Cells and the Dominance of Foxp3+CD4+ Graft Infiltrating Cells

  2013cites this paper
• Determining Disease Intervention Strategies Using Spatially Resolved Simulations

  2013cites this paper
• Manipulating T cell-mediated pathology: targets and functions of monoclonal antibody immunotherapy.

  2013cites this paper
• biologic therapies for inflammatory bowel diseases.

  2013cites this paper
• DIABETIC STUDIES The Review of Chapter IV . 2 CD 3 Monoclonal Antibodies : A First Step Towards Operational Immune Tolerance in the Clinic

  2013cites this paper
• Mechanisms of allergic diseases

  2013cites this paper
• The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases.

  2013cites this paper
• CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.

  2012cites this paper
• Asthma Prevention by Lactobacillus Rhamnosus in a Mouse Model is Associated With CD4+CD25+Foxp3+ T Cells

  2012cites this paper
• Current and future immunomodulation strategies to restore tolerance in autoimmune diseases.

  2012cites this paper
• Clinical immunologic interventions for the treatment of type 1 diabetes.

  2012cites this paper
• Pathogenesis and Medical Management of Thyroid Eye Disease

  2012cites this paper
• Long term amelioration of established collagen-induced arthritis achieved with short term therapy combining anti-CD3 and anti-TNF treatments

  2012cites this paper
• Low doses of anti-CD3, ciclosporin A and the vitamin D analogue, TX527, synergise to delay recurrence of autoimmune diabetes in an islet-transplanted NOD mouse model of diabetes

  2012cites this paper
• Targeting the B7 Family of Co-Stimulatory Molecules

  2012cites this paper
• Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases.

  2012cites this paper
• T Cell Apoptosis and Induction of Foxp3+ Regulatory T Cells Underlie the Therapeutic Efficacy of CD4 Blockade in Experimental Autoimmune Encephalomyelitis

  2012cites this paper
• Autoimmune Encephalomyelitis Efficacy of CD4 Blockade in Experimental Regulatory T Cells Underlie the Therapeutic + T Cell Apoptosis and Induction of Foxp3

  2012cites this paper
• Induction of Allograft Tolerance by Monoclonal CD3 Antibodies: A Matter of Timing

  2012cites this paper
• FOXP3 and RORγt: transcriptional regulation of Treg and Th17.

  2011influential citation
• Control of TH17 cells occurs in the Small Intestine

  2011cites this paper
• A natural anti-T-cell receptor monoclonal antibody protects against experimental autoimmune encephalomyelitis.

  2011cites this paper
• Gold Standard Animal Models

  2011cites this paper
• Prevention of experimental diabetes by Uncaria tomentosa extract: Th2 polarization, regulatory T cell preservation or both?

  2011cites this paper
• Anti-CD3 antibody ameliorates experimental autoimmune uveitis by inducing both IL-10 and TGF-β dependent regulatory T cells.

  2011cites this paper
• Induction of Immunological Tolerance by Oral Anti-CD3

  2011influential citation
• Immunomodulatory activity of mesenchymal stem cells.

  2011cites this paper
• Otelixizumab in the treatment of type 1 diabetes mellitus.

  2011cites this paper
• Développement d'immunothérapies spécifiques pour le traitement de l'hépatite autoimmune de type 2 chez un modèle murin

  2011cites this paper
• Anti-CD3 Therapy Promotes Tolerance by Selectively Depleting Pathogenic Cells while Preserving Regulatory T Cells

  2011cites this paper
• Monoclonal antibodies: The immune system and haematological malignancies

  2011cites this paper
• Prospects for antigen-specific tolerance based therapies for the treatment of multiple sclerosis.

  2010cites this paper
• Immunotherapy of type 1 diabetes: where are we and where should we be going?

  2010cites this paper
• Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor–specified peripheral niche constraints

  2010cites this paper
• New generation CD3 monoclonal antibodies: are we ready to have them back in clinical transplantation?

  2010cites this paper
• Have we overestimated the benefit of human(ized) antibodies?

  2010cites this paper
• ANTI-CD3 therapy expands the numbers of CD4+ and CD8+ Treg cells and induces sustained amelioration of collagen-induced arthritis.

  2010cites this paper
• CD3 mAb treatment ameliorated the severity of the cGVHD-induced lupus nephritis in mice by up-regulation of Foxp3+ regulatory T cells in the target tissue: kidney.

  2010cites this paper
• Immune therapy for type 1 diabetes mellitus—what is unique about anti-CD3 antibodies?

  2010cites this paper
• Immunopathogenesis of thyroid eye disease: emerging paradigms.

  2010cites this paper
• Pharmacokinetics and Pharmacodynamics of a Chimeric/Humanized Anti‐CD3 Monoclonal Antibody, Otelixizumab (TRX4), in Subjects With Psoriasis and With Type 1 Diabetes Mellitus

  2010cites this paper
• FOXP 3 and ROR γ t : Transcriptional regulation of Treg and Th 17

  2010influential citation
• Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases

  2010cites this paper
• Novel ways to attack inflammation in thyroid eye disease

  2010cites this paper
• Tolerance Induction and The Immunobiology of Factor VIII in Hemophilia A

  2010cites this paper
• Protective autoimmunity in the nervous system.

  2009cites this paper
• Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.

  2009cites this paper
• Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response.

  2009cites this paper
• Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.

  2009cites this paper
• Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity

  2009cites this paper
• Molecular mechanisms of T‐cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy

  2009cites this paper
• Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model.

  2009influential citation
• Immunological Tolerance: Therapeutic Induction

  2009cites this paper
• Evolução in vitro de anticorpos anti-CD3 pela seleção de cadeias leve (VL) humanas por phage display

  2009cites this paper
• CD3-specific antibodies to restore tolerance in autoimmune diabetes

  2009cites this paper
• Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion.

  2009cites this paper
• Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells

  2009cites this paper
• Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.

  2008cites this paper
• CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in type 1 diabetes.

  2008cites this paper
• The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic.

  2008cites this paper
• Factors regulating apoptosis and homeostasis of CD4+ CD25(high) FOXP3+ regulatory T cells are new therapeutic targets.

  2008cites this paper
• In vitro induction of regulatory T cells by anti-CD3 antibody in humans.

  2008cites this paper
• Nasal Anti-CD3 Antibody Ameliorates Lupus by Inducing an IL-10-Secreting CD4+CD25−LAP+ Regulatory T Cell and Is Associated with Down-Regulation of IL-17+CD4+ICOS+CXCR5+ Follicular Helper T Cells1

  2008cites this paper
• Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary

  2008cites this paper
• Anti-CD3: from T cell depletion to tolerance induction

  2008cites this paper
• Essential roles of TGF‐β in anti‐CD3 antibody therapy: reversal of diabetes in nonobese diabetic mice independent of Foxp3+CD4+ regulatory T cells

  2008cites this paper